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The Whole Side of It—
An Interview with Neil Risch
Jane Gitschier
T
rying to track down Neil Risch is
the stuff of legend. E-mails to
him can bounce back with the
comment line ‘‘overwhelmed by email.’’
Phone calls lead to voicemail, and faxes
to a tepid response from his assistant.
It’s not that he’s reclusive or off
windsurﬁng, he’s simply a whirlwind of
genetics ideas and activity.
Indeed, when the University of
California at San Francisco was looking
for a director of the new Center for
Human Genetics, Neil’s name quickly
came to the top of the heap. With wide-
ranging experience and interests, he
was described by one of the ﬁeld’s
founding fathers as ‘‘the statistical
geneticist of our time.’’ It didn’t hurt
that he is a mensch.
I managed to trap Neil in his bright
new ofﬁce on the ninth ﬂoor of the
west tower off Parnassus Avenue. Still
spartan, with only a computer, a phone,
and a chair, the ofﬁce’s view spanned
Golden Gate Park, the Marin
headlands, and the Paciﬁc Ocean. The
vista was interrupted only by the
jarring copper-clad tower of the new
museum under construction in Golden
Gate Park. It was a brilliant blue, warm
afternoon, and I looked forward to
spending some one-on-one time with
this man, with his infectious laugh and
his intellectual stamina.
Jane Gitschier: Let’s start with the
broad view. What really interests you?
Neil Risch: My passion, really, is the
interplay between population genetics
and clinical applications—to see the
whole side of it.
When I was in graduate school, I
came out of math. Three weeks into my
ﬁrst course in human genetics [as part
of a new biomathematics graduate
program at the University of California
at Los Angeles], I knew that it was what
I wanted to do. One, I loved the subject
matter. Two, I loved the quantitative
aspect of it. Three, I loved the intuitive
aspect of it. It was almost like I could
predict the next lecture. It was a
perfect ﬁt for me. My other passion was
population genetics, but there weren’t
many career opportunities in that ﬁeld
back then. So always there was this
latent passion for population genetics
without the opportunity to act on it.
The thing that has been exciting for
me is that I saw ten years ago where the
ﬁeld was going. Having the sequence of
the human genome provides the
opportunity to look at the variation in
that sequence as well, which leads to
the marriage of several areas, but
particularly human population
genetics with disease studies—genetic
epidemiology.
But the ﬁelds have never been so
intimately related as they are now, and
I am just thrilled. I get to marry the two
things I love to do. In the old days, the
NIH [National Institutes of Health]
would never fund a study in population
genetics, but now it does because you
need to understand human population
history and genetics to undertake all
these studies of human genetic
variation underlying disease
susceptibility.
Gitschier: So many people want to
collaborate with you. How do you
choose what projects to become
involved with? Did you initiate most of
the projects you work on, or do people
come to you?
Risch: In my Stern Award address
[presented to the American Society of
Human Genetics in 2004], I talked
about the population genetics analogy
of selection and drift. Some things are
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them, and some things are just random.
Some things I have become interested
in and I have initiated, and other things
have come to me and I’ve participated
in them either because it was
appropriate, given the setting where I
was working, or I was interested in the
project and wanted to have a collegial
relationship.
There has been quite a range of the
projects I have gotten involved in,
especially on the clinical side. I think
it’s been good for me that I haven’t
focused on one particular area, like
cancer or psychiatry. Some people
could say, ‘‘He’s like a dilettante,’’ but I
think it has given me a broad
perspective on the clinical application
and the commonalities in terms of the
issues involved across diseases, and
some of the unique aspects. I value the
fact that I’ve been able to be involved in
a lot of different things. I feel
incredibly fortunate to have become
established in a ﬁeld so that I’ve had a
lot of opportunities in terms of
different people approaching me for
collaborations. It’s been great.
Gitschier: You are an Ashkenazi Jew
and belong to a conservative temple
here in San Francisco. You also are well
known for your work on diseases, such
as torsion dystonia, that affect this
particular population. Do you think
you gravitate to these problems
because of your ethnicity?
Risch: Early on, I was interested in
population genetics and I knew about
this debate about the presence of the
lysosomal storage diseases in the Jews.
Why did the Jews have all these
diseases?
Gitschier: I just assumed it was selective
advantage. What was the debate?
Risch: Between selection and drift—as
it always is.
This actually started with the
dystonia work. At the time, there was a
raging question about the mode of
inheritance. They knew it [severe early-
onset idiopathic torsion dystonia] was
more prevalent in Ashkenazi Jews.
Some people thought it was dominant,
but there was a major paper that said it
was recessive just like all other major
Ashkenazi diseases.
And I was interested. It was a nice
statistical problem, and it was in the
Jewish population, which I was
interested in both for scientiﬁc and
historical reasons, and because of my
own identity.
So we did a study. Susan Bressman,
my colleague at Columbia,
systematically went out and clinically
examined all the ﬁrst- and second-
degree relatives of all the early-onset
Jewish cases—parents, siblings,
children, nieces and nephews, half-sibs,
uncles and aunts, maybe grandparents.
We analyzed the data, and the rates of
dystonia in the relatives were the same
in all the ﬁrst-degree relatives; the
siblings did not have a higher risk.
About 15% for everybody, across the
board. We concluded that it was
autosomal dominant with low
penetrance [30%].
We did a formal segregation analysis.
We could clearly, overwhelmingly
reject a recessive model. And at the
time I thought, ‘‘Well, this is
fascinating!’’ because we had a
dominant disease with a founder effect
in the Jewish population. And we even
suggested that this would be valuable
for gene mapping—by linkage
disequilibrium [LD] analysis. And after
mapping the disease, we found strong
LD right away. So this was very clear
evidence that we were dealing with a
relatively recent founder mutation.
I know this is a long story, but it was
through that project that I got
interested in Jewish population
genetics.
Gitschier: It seems as though every time
I open the science section of the New
York Times, you are featured in it. These
articles, at least lately, focus on your
adherence to an often politically
incorrect idea, such as the genetic basis
for race or the way NIH should spend
its money on diseases of addiction. Do
you deliberately choose controversy?
Risch: I think historically I have
avoided it. Perhaps this is what job
security offers you—the opportunity to
get involved in potentially more
controversial questions. And I think
I’ve decided that playing it safe is not
the way to go. I just don’t believe that
anymore. These are big important
subjects and I just don’t think they
should be avoided.
Gitschier: Let’s talk about the former,
the genetic basis of race. As you know, I
went to a session for the press at the
ASHG [American Society for Human
Genetics] meeting in Toronto, and the
ﬁrst words out of the mouth of the ﬁrst
speaker were ‘‘Genome variation
research does not support the existence
of human races.’’
Risch: What is your deﬁnition of races?
If you deﬁne it a certain way, maybe
that’s a valid statement. There is
obviously still disagreement.
Gitschier: But how can there still be
disagreement?
Risch: Scientists always disagree! A lot
of the problem is terminology. I’m not
even sure what race means, people use
it in many different ways.
In our own studies, to avoid coming
up with our own deﬁnition of race, we
tend to use the deﬁnition others have
employed, for example, the US census
deﬁnition of race. There is also the
concept of the major geographical
structuring that exists in human
populations—continental divisions—
which has led to genetic
differentiation. But if you expect
absolute precision in any of these
deﬁnitions, you can undermine any
deﬁnitional system. Any category you
come up with is going to be imperfect,
but that doesn’t preclude you from
using it or the fact that it has utility.
We talk about the prejudicial aspect
of this. If you demand that kind of
accuracy, then one could make the
same arguments about sex and age!
You’ll like this. In a recent study,
when we looked at the correlation
between genetic structure [based on
microsatellite markers] versus self-
description, we found 99.9%
concordance between the two. We
actually had a higher discordance rate
between self-reported sex and markers
on the X chromosome! So you could
argue that sex is also a problematic
category. And there are differences
between sex and gender; self-
identiﬁcation may not be correlated
with biology perfectly. And there is
sexism. And you can talk about age the
same way. A person’s chronological age
does not correspond perfectly with his
biological age for a variety of reasons,
both inherited and non-inherited.
Perhaps just using someone’s actual
birth year is not a very good way of
measuring age. Does that mean we
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ageism—prejudice related to age in our
society. A lot of these arguments, which
have a political or social aspect to
them, can be made about all categories,
not just the race/ethnicity one.
Gitschier: I have heard you say, ‘‘Don’t
politicize the human genome.’’
Risch: I have a strong problem with the
way politicians use this information.
[Former President] Clinton, for
example, when the ﬁrst draft of the
human genome sequence came out,
made a statement about how all people
in the world, in terms of their genetic
makeup, are 99.9% the same. His
intent—to reduce conﬂict among
peoples—is noble. People on the left,
anthropologists and sociologists, do the
same thing. They use the 99.9% ﬁgure
as an argument for social equality. But
the truth is that people do differ by
that remaining 0.1% and that people
do cluster according to their ancestry.
The problem is that others could use
that information to create division.
Gitschier: Do you ever feel that the
press misrepresents you?
Risch: Don’t we all feel that to some
extent? They always take the simple
side, which leads to misinterpretation.
So there are risks in talking to the
press, especially on controversial
subjects.
Gitschier: You have a brother who is an
academic, and at one point you and he
were both on the faculty at Yale. Is that
genetic? Tell us about the environment
that you grew up in that ultimately led
to producing two academicians. I don’t
know what your brother’s ﬁeld is.
Risch: So interesting. You tell me, is this
‘‘nature’’ or ‘‘nurture’’?
My brother, my only sibling [Harvey
Risch], is 20 months older than I.
Mathematics was his skill set also. He
went to Cal Tech, starting a year
before me—both of us math majors.
Then he decided to go to medical
school, so he did additional
coursework, and we graduated
simultaneously. He went to UCSD to
medical school, and had to do a
thesis—so he came to UCLA in my
department and lived with me. Then
he applied to do a PhD in
biomathematics in my department [but
went to the University of Chicago
instead]. His ﬁrst paper and my ﬁrst
paper appeared in the same issue of
Annals of Human Genetics, and we didn’t
even know it. Then Harvey decided to
do epidemiology as a post-doc, while I
was learning epidemiology at
Columbia. Our grades, SAT scores,
GRE scores—everything pretty much
the same.
Gitschier: Sounds like the premise for a
simple quantitative analysis. Do you
think you are both hardwired to do
mathematical problems? Or did your
family just sit around at dinner doing
math problems?
Risch: Not at all. My mom [Sonia Risch]
was very artistic and intuitive. Great
artist, writer, actress—and brilliant at
all of it. My father was a clinical
psychiatrist. But if you look at my
family history, on my mother’s side
there are a lot of MDs and on my
father’s side there is a lot of math. So if
you want to make a genetic hypothesis
here, my brother is the conﬂuence of
both, maybe, and maybe me, too. My
brother and I would talk about stuff a
lot. My mother would say, ‘‘Oh, they’re
talking Fortran.’’




see the whole side of it.’’
Gitschier: You have been working with
the epidemiologists at Kaiser Perma-
nente [a health-care provider] in Oak-
land for the past seven years. I under-
stand you spend every Wednesday
there. How did this collaboration come
about, and what is it you are trying to
accomplish? Other than numbers, is
there something the Kaiser resource
can do that say, Iceland, couldn’t?
Risch: Can it ever!
Gitschier: Why don’t you tell me what’s
so cool about it?
Risch: When I went to Stanford, at the
back of my mind was this issue about
Kaiser. This comes from my
epidemiology background. This is the
advantage of being multidisciplinary. If
I could push anything, it’s the value of
seeing the links between various
disciplines and marrying them. One,
Kaiser’s membership is a cohort—you
don’t have to construct it from scratch.
And it’s followed over time, for many
people over 20 years. Two, they have
computerized databases where every
contact a patient has with the health-
care system, every inpatient,
outpatient, and pharmacy visit, every
visit with doctors outside the Kaiser
system gets recorded, every X ray, every
lab test, basic biochemistries—all
computerized. Three, it is the health-
care provider for one-third of the Bay
Area and a very good representation of
Bay Area population. It is missing only
the very high and very low end of the
socioeconomic ladder. All major ethnic
groups are represented. To me, it’s the
most wonderful laboratory for doing
population genetic and genetic
epidemiologic research.
As you can tell, I’m a very strong
believer of inclusion of a variety of
people of varying racial/ethnic
backgrounds in research. There is
everything to be gained from doing
so—not just politically, but
scientiﬁcally. Also, ethically it’s the
right thing to do. And I’m concerned in
this whole discussion that people may
be scared off from the genetics
research and that’s the battle.
One big issue that I think will go a
long way towards addressing this
problem is to do everything we can to
recruit more minority scientists to
human genetics. For the research to
have credibility in minority
communities, there must be
representation from those
communities among scientists. And I
want to be involved in that process also.
Gitschier: In Iceland, you’ve got all the
ancestry data, and so you can do
traditional linkage analysis, but in
Kaiser, you’re going to do association
studies.
Risch: That’s right. Because of the way
the technology is moving, this is a
tremendous resource for doing that.
Gitschier: This is a very long-term
study. There must be an element of
‘‘Oh, I see this gelling’’ and it just can’t
go fast enough.
Risch: You’re right, it’s been a long
process. There are complexities and
ﬁnancial issues.
This is really the best opportunity we
have in the United States to do
something along these lines, and it’s
been a little frustrating that it’s been
difﬁcult to get the support and funding
for it, but I’m patient. Because when
you believe in something and know it’s
right, you have the patience to see it
though. n
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